Confident Buy Rating for Surgery Partners Amidst Growth and …

5 days ago · The attractive valuation at 12.1x EV/EBITDA, compared to anticipated revenue and EBITDA growth rates, along with a robust investment pipeline, supports the Buy rating, especially given the ...

CouponFollow Extension

$26.49
OFF

Surgery Partners (SGRY) Enterprise Value - Zacks.com

1 week from now

4 days ago · Surgery Partners Inc (SGRY) Shares Gap Down to $26.4925 on Nov 13 11/13/24-10:24AM EST GuruFocus Confident Buy Rating for Surgery Partners Amidst Growth and …

zacks.com

76%
OFF

TD Cowen Cuts Surgery Partners Stock Target, Retains Buy On …

1 week from now

4 days ago · SGRY. -13.76%. On Thursday, TD Cowen adjusted its outlook on Surgery Partners (NASDAQ: SGRY) shares, a leading healthcare services company. The firm's analyst, Ryan …

investing.com

$44.44
OFF

9 Analysts Assess Surgery Partners: What You Need To Know

1 week from now

Oct 4, 2024 · Analysts have recently evaluated Surgery Partners and provided 12-month price targets. The average target is $44.44, accompanied by a high estimate of $50.00 and a low …

nasdaq.com

$42.25
OFF

What 8 Analyst Ratings Have To Say About Surgery Partners

1 week from now

Aug 19, 2024 · Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.25, a high estimate of $50.00, and a low estimate of $31.00. Observing a …

nasdaq.com

25%
OFF

Surgery Partners Scores Relative Strength Rating Upgrade; Hits …

1 week from now

Oct 15, 2024 · EPS growth fell in the company's most recent report from 25% to -25%, but sales rose from 8% to 14%. ... earning an upgrade to its IBD Relative Strength Rating 10/09/2024 …

investors.com

20%
OFF

Surgery Partners (SGRY) Upgraded To Buy: What Does It Mean For …

1 week from now

Mar 20, 2024 · The upgrade of Surgery Partners to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move …

nasdaq.com

$40
OFF

Jefferies Cuts Surgery Partners Target To $40, Maintains Buy Rating

1 week from now

5 days ago · In summary, while there has been a reduction in the price target for Surgery Partners, Jefferies continues to view the stock favorably with a Buy rating. The firm …

investing.com

25%
OFF

Stocks With Rising Relative Strength: Surgery Partners

1 week from now

Oct 10, 2024 · Surgery Partners is working on a cup with handle with a 33.97 . See if the stock can break out in heavy trading. EPS growth declined last quarter from 25% to -25%, but sales …

investors.com

$47.00
OFF

Surgery Partners: A Buy Rating Amidst Underperformance And …

1 week from now

Mar. 29, 2024, 02:07 AM. Analyst Whit Mayo of Leerink Partners reiterated a Buy rating on Surgery Partners (SGRY – Research Report), retaining the price target of $47.00. Whit Mayo …

businessinsider.com

$40
OFF

Critical Insights From Surgery Partners Analyst Ratings: What

1 week from now

Jun 28, 2024 · In the assessment of 12-month price targets, analysts unveil insights for Surgery Partners, presenting an average target of $40.5, a high estimate of $50.00, and a low estimate …

nasdaq.com

14%
OFF

Jefferies Cuts Surgery Partners Target To $40, Maintains Buy Rating

1 week from now

5 days ago · In other recent news, Surgery Partners reported a robust third quarter in 2024, with net revenue climbing 14% year-over-year to $770 million. The company's adjusted EBITDA …

investing.com

FAQs about Confident Buy Rating for Surgery Partners Amidst Growth and … Coupon?

How did surgery partners perform compared to consensus expectations?

Despite a slight miss in adjusted EPS compared to consensus expectations, Surgery Partners demonstrated strong year-over-year growth in adjusted EBITDA, which slightly exceeded projections. The firm’s consolidated revenue also surpassed expectations, indicating robust operational performance. ...

Why has Ryan Langston rated Surgery Partners a buy?

Ryan Langston has given his Buy rating due to a combination of factors relating to Surgery Partners’ financial performance and market positioning. The company’s revenue and adjusted EBITDA surpassed consensus expectations, with a particularly optimistic outlook for the second half of 2024, prompting an increase in full-year guidance. ...

Why has Surgery Partners underperformed?

Mayo notes that despite the general upward trend in healthcare providers, Surgery Partners has underperformed, which he attributes to factors such as the overhang from its equity sponsor Bain, softer same-store case growth, and lower cash flow targets for 2024. ...

Why is a Buy rating based on a reaffirmation of 2024 guidance?

The firm’s consolidated revenue also surpassed expectations, indicating robust operational performance. Another factor contributing to the Buy rating is the reaffirmation of the company’s 2024 guidance, showing confidence in achieving substantial adjusted EBITDA and net revenue targets. ...

What does surgery partners do?

Surgery Partners, Inc. is healthcare services holding company, which engages in the provision of solutions for surgical and related ancillary care in support of its patients and physicians. It operates through the following business segments: Surgical Facility Services, Ancillary Services, and Optical Services. ...